Managing recurrent parvovirus B19-associated anemia after a pediatric kidney transplant
Open Access
- 22 May 2024
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 39 (10) , 2923-2925
Abstract
A 13-year-old girl who had a kidney transplant four weeks prior presented with a 10-day history of fatigue, paleness, and headache. On physical examination, tachycardia and paleness were noted. Laboratory testing was notable for severe anemia and mild leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) test for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were negative and for parvovirus B19 (PVB19) was positive. Despite lower immunosuppression and administration of intravenous immunoglobulin (IVIG) it persisted for 15 months, and frequent red blood cell transfusions were needed. PVB19 is a less common but significant complication. The patient's clinical course demonstrates the importance of this complication and the challenges in its management. A notable void exists in the literature regarding standardized treatment protocols for PVB19-induced recurrent anemia after kidney transplant. This case indicates the need for further research and consensus to guide effective clinical interventions in similar cases.Keywords
Funding Information
- istinye University
This publication has 6 references indexed in Scilit:
- A case of recurrent anemia due to chronic parvovirus B19 infection in a kidney transplant recipient. Can everolimus make a difference?CEN Case Reports, 2021
- Epidemiology of parvovirus B19 and anemia among kidney transplant recipients: A meta-analysisUrology Annals, 2020
- Risk factors and long‐term outcomes of parvovirus B19 infection in kidney transplant patientsTransplant Infectious Disease, 2017
- Human Parvovirus B19 in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Parvovirus B19 Infection after Transplantation: A Review of 98 CasesClinical Infectious Diseases, 2006
- Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapyNephrology Dialysis Transplantation, 2002